Global Antibacterial Drugs Market 2015-2019 - Covering Key Manuffacturers (Allergan, GlaxoSmithKline, Merck, Novartis, Pfizer & Teva Pharmaceuticals)

Albany, NY, Feb 23, 2017: Antibacterial drugs are chemical compounds used to treat infections caused by bacteria either by killing or inhibiting the growth of bacteria. The term antibiotic is often used synonymously with an antibacterial. However, antibiotics are agents that work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. The term antibiotic was originally coined to refer to any compound of microbial origin, which is antagonistic to the growth of the microbe. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. They can be bacteriostatic or bactericidal in nature, i.e., they either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad-spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).

The global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019. In this report, Technavio covers the present scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The various classes of antibacterial drug included in this report are beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, folate antagonists, tetracyclines, and other miscellaneous agents, which include glycopeptides, nitroimidazoles, lincosamides, lipopeptides, nicotinic acid derivatives, and polypeptide antibiotics.

Get a Sample Research PDF with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=459067

Technavio's report, Global Antibacterial Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Teva Pharmaceuticals

Other prominent vendors
- Abbott
- Achaogen
- Actelion
- AmpliPhi Biosciences
- Aspen Pharmacare
- Astellas
- AstraZeneca
- Aurobindo Pharma
- Baxter
- Basilea Pharmaceuticals
- Bayer
- Biocon
- Bristol-Myers Squibb
- Cempra
- Cipher Pharmaceuticals
- Corden Pharma
- Cornerstone Therapeutics............

Enquiry at: http://www.researchmoz.us/enquiry.php?type=E&repid=459067

Key questions answered in the report include
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

This release was published on openPR.